NCT06101082
A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Mar 2024); last known: Recruiting
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Oct 25, 2023 to Jan 16, 2024
- Site details revised
- Minor Study title shortened, about 7 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Dose-limiting toxicity
Timeframe: 21 days within anti-HER2-CAR-T cell infusion
Secondary (1)
Objective response rate
Arms and interventions
Anti-HER2-CAR-T cell infusionExperimental
Anti-HER2-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 1×10\^6 CAR-T cells/kg, 3×10\^6 CAR-T cells/kg, and 1×10\^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.The patients will receive lymphocyte clearance therapy with cyclophosphamide and fludarabine before the infusion.
Biologicals: Intravenous infusion anti-HER2-CAR-T cell
Sites
1 site in 1 country
- Phase I Clinical Trials Center Of The First Hospital of China Medical UniversityShenyang, Liaoning, China